Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835368 | 1.00 | PDE4B (0.48) | PDE4BNR1H2KDM1AUSP30PIK3CD | |
| SCHEMBL27462772 | 0.93 | KDM1A (0.53) | PDE4BNR1H2KDM1APDE4APDE4C | |
| SCHEMBL16980643 | 0.87 | GPR119 (0.51) | PDE4BNR1H2KDM1AUSP30PIK3CD | |
| SCHEMBL4202107 | 0.87 | PDE4B (0.59) | PDE4BNR1H2KDM1AUSP30PIK3CD | |
| SCHEMBL16980860 | 0.87 | GPR119 (0.51) | PDE4BNR1H2KDM1AUSP30PIK3CD | |
| SCHEMBL15509004 | 0.87 | PDE4B (0.59) | PDE4BNR1H2KDM1AUSP30PIK3CD | |
| SCHEMBL4202110 | 0.87 | PDE4B (0.59) | PDE4BNR1H2KDM1AUSP30PIK3CD | |
| SCHEMBL29947729 | 0.86 | PDE4B (0.45) | PDE4BKDM1AUSP30PIK3CDPIK3CA | |
| SCHEMBL26633333 | 0.86 | PDE4B (0.45) | PDE4BKDM1AUSP30PIK3CDPIK3CA | |
| SCHEMBL30912524 | 0.85 | PDE4B (0.52) | PDE4BNR1H2KDM1AUSP30PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147427-A1 | PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE | LEAD DISCOVERY CENTER GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2019197549-A1 | PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE | QURIENT CO., LTD. (KR) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147427-A1 | PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE | CDK1, CDK2, CDK15 | PDE4B 1516/4885NR1H2 3422/4885KDM1A 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.